Latest News and Press Releases
Want to stay updated on the latest news?
Featured Releases
-
WUYI, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- On December 6, the 2025 "Silk Road for All Children" International Children's Literature Week and the 10th Fairy Tale Conference was held in Wuyi,...
Read More -
DUBAI, United Arab Emirates, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) has reached a new presale milestone, surpassing $19.2 million in funding as its ongoing offering approaches full...
Read More
-
WUYI, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- On December 6, the 2025 "Silk Road for All Children" International Children's Literature Week and the 10th Fairy Tale Conference was held in Wuyi,...
-
DUBAI, United Arab Emirates, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) has reached a new presale milestone, surpassing $19.2 million in funding as its ongoing offering approaches full...
-
Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting Millions
-
Beijing, China, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Chinese President Xi Jinping and visiting French President Emmanuel Macron had friendly exchanges on Friday in Dujiangyan in Chengdu, capital city...
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Today, SALI, China's leading power tool accessories brand, made a grand appearance on Nasdaq's iconic billboard in Times Square. Under the theme "The...
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and...
-
ThinkCareBelieve's Week 46 Article hails the Trump Administration for intense and important progress.
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of investors in...
-
NEW YORK, Dec. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America’s...
-
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up...